Tumours with dysregulated MHC class I expression (e.g. due to acquired or intrinsic mutations in genes encoding β2-microglobulin or members of the JAK-STAT-IFNγ signalling pathway) [39] may be better targeted by CARs rather than engineered TCRs in conjunction with OVs. The gene discussed is IFNG; the disease is neoplasm.